Alluvi, previously BI 4744, presents a promising advance in obesity treatment. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates remarkable efficacy in https://bookmarkworm.com/story22070336/alluvi-a-detailed-examination-into-the-retatrutide-s-potential